{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-25-001428","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.111393+00:00","generated_at":"2026-05-17T03:51:32.454779+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IGC Pharma shareholders approve 4x increase in authorized shares to 600M and 5M share grant","bullets":["Shareholders approved amendment to increase authorized common stock from 150M to 600M shares.","Approved grant of up to 5M shares for employees, advisors, directors, and consultants under performance metrics.","Re-elected directors Ram Mukunda and James Moran as Class C directors until 2028.","Ratified Manohar Chowdhry & Associates as independent auditor for fiscal 2026.","Non-binding advisory vote set frequency of executive compensation votes every three years."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-25-001428","json":"https://secwatch.observer/filing/0001185185-25-001428.json","markdown":"https://secwatch.observer/filing/0001185185-25-001428.md","text":"https://secwatch.observer/filing/0001185185-25-001428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518525001428/0001185185-25-001428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518525001428/igc8k101025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:51:32.454779+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}